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In accordance with Article 5 of Council Decision 2005/387/JHA on 
the information exchange, risk assessment and control of new 
psychoactive substances 
About this series
EMCDDA–Europol Joint Report publications examine the detailed information 
provided by the EU Member States on individual new psychoactive substances. 
Information is collected from the Reitox network, the Europol National Units and the 
national competent authorities of the European Medicines Agency.
Each Joint Report serves as the basis upon which the decision to conduct a risk 
assessment of the new psychoactive substance is taken. It is part of the three-step 
procedure involving information exchange, risk assessment and decision-making in the 
framework of Council Decision 2005/387/JHA.
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I 1. Introduction
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter 
the ‘Council Decision’) stipulates that ‘Where Europol and the 
EMCDDA, or the Council, acting by a majority of its members, 
consider that the information provided by the Member State 
on a new psychoactive substance merits the collection of 
further information, this information shall be collated and 
presented by Europol and the EMCDDA in the form of a Joint 
Report.’ The Joint Report shall be submitted to the Council of 
the European Union, the European Medicines Agency (EMA), 
and the European Commission.
In March 2017, the EMCDDA and Europol examined the 
available information on the new psychoactive substance 
methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-
3,3-dimethylbutanoate, commonly known as 5F-MDMB-
PINACA, through a joint assessment based upon the following 
criteria:
1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6. evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information 
collected on 5F-MDMB-PINACA satisfied criteria 1, 4, 5 and 6. 
The two agencies therefore concluded that sufficient 
information had been accumulated to merit the production of 
a Joint Report on 5F-MDMB-PINACA as stipulated by Article 
5.1 of the Council Decision.
I 2. Information collection process
In compliance with the provisions of the Council Decision, on 
25 April 2017 the EMCDDA and Europol launched a procedure 
for the collection of information on 5F-MDMB-PINACA, in 
order to prepare the Joint Report. The information was 
collected mainly through the Reitox national focal points in the 
Member States, Turkey and Norway as well as the Europol 
National Units. In addition, the EMA collected information 
through the national competent authorities responsible for 
human and veterinary medicinal products in the Member 
States as well as in Norway, Iceland and Liechtenstein. The 
EMA also provided information as relevant to the centralised 
procedure for authorising medicinal products. The information 
collection process was largely concluded by 6 June 2017.
(1) OJ L 127, 20.5.2005, p. 32. 
Information collected by Europol
Europol asked the Europol National Units to provide 
information on:
 ¡ the level of production of 5F-MDMB-PINACA in their 
country;
 ¡ the level of distribution of 5F-MDMB-PINACA in their 
country;
 ¡ the level of trafficking of 5F-MDMB-PINACA in their country, 
both for internal, transit or export purposes;
 ¡ the number of seizures of 5F-MDMB-PINACA in their 
country, the total amount of the seizures, country of origin, 
details on the physical forms (including photos);
 ¡ the role of organised crime or criminal groups, in the 
production, distribution and trafficking of 5F-MDMB-
PINACA in their country;
 ¡ any known aspect of violence and/or money laundering 
relating to the production and trafficking of 5F-MDMB-
PINACA.
Europol received responses from 15 Member States (2).
Information collected by the EMA
According to Article 5.3 of the Council Decision, the EMA 
requested that the national competent authorities responsible 
for human and veterinary medicinal products in the Member 
States, Norway, Iceland and Liechtenstein, provide information 
on whether:
 ¡ the new psychoactive substance 5F-MDMB-PINACA has 
obtained a marketing authorisation;
 ¡ the new psychoactive substance 5F-MDMB-PINACA is the 
subject of an application for a marketing authorisation;
 ¡ a marketing authorisation that had been granted in respect 
of the new psychoactive substance 5F-MDMB-PINACA has 
been suspended.
Twenty-three countries provided a response to the EMA’s 
request regarding human and/or veterinary medicinal 
products (3). The EMA also provided information as relevant to 
the centralised procedure for authorising human and 
veterinary medicinal products.
(2) In alphabetical order: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech 
Republic, Finland, Germany, Greece, Latvia, Lithuania, Luxembourg, Romania, 
Slovakiaand Slovenia.
(3) Austria, Belgium, Denmark, Estonia, Finland, Germany, Greece, Ireland, Latvia, 
Norway, Poland, Spain, Sweden and the United Kingdom provided a response in 
relation to human and veterinary medicinal products. Croatia, Czech Republic, 
Hungary, Italy and the Netherlands provided a response in relation to human 
medicinal products. France, Portugal, Slovakia and Slovenia provided a response 
in relation to veterinary medicinal products.
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Furthermore, in anticipation of Article 7.3 of the Council 
Decision in relation to the manufacturing of medicinal 
products in the European Union, the EMA also requested 
information on whether the new psychoactive substance 
5F-MDMB-PINACA is used to manufacture a medicinal 
product:
 ¡ which has been granted a marketing authorisation;
 ¡ for which an application has been made for a marketing 
authorisation;
 ¡ for which a marketing authorisation has been suspended 
by a competent authority.
Twenty-three countries (4) provided a response to the EMA’s 
request in this regard. The EMA also provided information as 
relevant to the centralised procedure for authorising human 
and veterinary medicinal products.
Information collected by the EMCDDA
The EMCDDA collected information through:
 ¡ a structured questionnaire to the Reitox national focal 
points. The EMCDDA received replies from 27 Member 
States (5), as well as Turkey and Norway;
 ¡ reports previously provided to the European Union Early 
Warning System, including EMCDDA–Europol Reporting 
Forms and Progress Reports and Final Reports;
 ¡ routine monitoring of open source information;
 ¡ a specific information request to the World Health 
Organization on whether or not 5F-MDMB-PINACA is under 
assessment by the United Nations system;
 ¡ a search of open source information conducted specifically 
for the production of the Joint Report which included: 
scientific and medical literature, official reports, grey 
literature, internet drug discussion forums and related 
websites (hereafter, ‘user websites’) and online vendors 
selling 5F-MDMB-PINACA.
Thus, the information included in sections 3.2.1 and 3.3 of the 
Joint Report was provided by Europol, while the EMCDDA 
provided information included in sections 3.1, 3.2.2, 3.4, 3.5, 
3.6, 3.7, 3.8.1, 3.8.2 and 3.8.3 (in part). The information 
included in sections 3.8.3 (in part) and 4 was provided by the 
EMA. Images of the seizures and collected samples reported 
to the EMCDDA are provided in Annex 1.
(4) Austria, Belgium, Denmark, Estonia, Finland, Germany, Greece, Ireland, Latvia, 
Norway, Poland, Spain, Sweden and the United Kingdom provided a response in 
relation to human and veterinary medicinal products. Croatia, Czech Republic, 
Hungary, Italy and the Netherlands provided a response in relation to human 
medicinal products. France, Portugal, Slovakia and Slovenia provided a response 
in relation to veterinary medicinal products.
(5) A reply was not received from Slovakia. 
 3.  Information required by Article 5.2 of 
the Council Decision
The order and titles of subsections 3.1 to 3.8 and section 4, 
below, are as they appear in Article 5.2(a) to (h) and Article 
5.3(a) to (c) of the Council Decision; sections are cross-
referenced with those set down in the Council Decision.
 3.1  Chemical and physical description, including 
the names under which the new psychoactive 
substance is known (Article 5.2(a) of 
the Council Decision)
Chemical description and names
Methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-
3,3-dimethylbutanoate is commonly referred to as 5F-MDMB-
PINACA and/or 5-ADB (6).
5F-MDMB-PINACA is a synthetic cannabinoid receptor 
agonist. It appears not to have been described in the scientific 
or patent literature prior to the first detection on the drug 
market in Europe in 2014.
5F-MDMB-PINACA shares some structural features with 
MDMB-CHMICA (7) (8), which was risk-assessed in 2016 
(EMCDDA, 2016). MDMB-CHMICA will be controlled under 
Schedule II of the United Nations Convention on Psychotropic 
Substances of 1971 (9).
The molecular structure, molecular formula and molecular 
mass of 5F-MDMB-PINACA are provided in in Figure 1.
(6) The common name for the substance is derived after its structural features. 
Different naming systems exist and are used for applying short/code names to 
synthetic cannabinoids.
(7) Methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-
dimethylbutanoate.
(8) Both substances contain a methyl dimethyl butanoate linked group (MDMB) 
and a carboxamide linker (CA), however they differ due to the indazole core (INA) 
and 5-fluoropently (5F-P) moiety present in 5F-MDMB-PINACA, whereas 
MDMB-CHMICA has an indole core (I) with a cyclohexylmethyl moiety (CHM) 
present.
(9) Two synthetic cannabinoid receptor agonists have been recently controlled 
under the Schedule II of the United Nations Convention on Psychotropic 
Substances of 1971: JWH-018 (naphthalen-1-yl(1-pentyl-1H-indol-3-yl)
methanone) and AM-2201 (1-(5-fluoropentyl)-1H-indol-3-yl]-(naphthalen-1-yl)
methanone). In addition, MDMB-CHMICA, 5F-APINACA (5F-AKB48) and XLR-11 
will be also included in the same schedule. 
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5F-MDMB-PINACA contains a stereocentre thus allowing 
for the existence of a pair of enantiomers (10),  
(R)- and (S)-5F-MDMB-PINACA. Based on the patent 
literature of similar compounds (Buchler et al., 2009) and 
the  most likely precursors to be used, an (S)-configuration 
of the stereocentre could be expected. The synthesis of  
(S)-5F-MDMB-PINACA has been described by  
Banister et al. (Banister et al., 2016).
There is no representative information on the enantiomeric 
composition of the samples of 5F-MDMB-PINACA detected 
within the European Union, which in part may reflect the fact 
that stereochemical analysis is not routinely undertaken in 
forensic laboratories. Differentiation of enantiomers is 
possible using the following techniques: chiral 
chromatography, vibrational circular dichroism (VCD) 
spectroscopy and/or electronic circular dichroism (ECD) 
spectroscopy.
Commonly used names:  
5F-MDMB-PINACA; 5F-ADB
Systematic (IUPAC) name:  
methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-
3,3-dimethylbutanoate
Other chemical names (11):  
methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)- 
3,3-dimethylbutanoate;  
methyl-[2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-
3,3-dimethylbutanoate];  
(10) Optical isomers (or enantiomers) have the same physico-chemical 
characteristics, differing only in their interaction with plane polarized light.
(11) Names listed do not take into account the enantiomeric composition. 
N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(5-fluoropentyl)-
1H-indazole-3-carboxamide;  
valine, N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-3-
methyl-, methyl ester;  
1-(5-fluoropentyl)-3-(2-(methyl 3,3-dimethylbutanoate)
carbamoyl)indazole;  
metyl-2-(1-(5-fluoropentyl)-1H-indazol-3-karboxamido)-3,3-
dimetylbutanoat (Sweden)
Other names and code names:  
5F-methyl-AMB; 5-fluoro-MAMB; 5-fluoro ADB; 5-fluoro 
MDMB-PINACA; MDMB(N)-2201; 5FADB
Chemical Abstracts Service (CAS) registry numbers (12): 
1715016-75-3 5F-MDMB-PINACA racemate 
1838134-16-9 (R)-5F-MDMB-PINACA 
1971007-89-2 (S)-5F-MDMB-PINACA
IUPAC International Chemical Identifier Key (InCHI Key) (13):  
PWEKNGSNNAKWBL-UHFFFAOYSA-N 5F-MDMB-PINACA racemate 
PWEKNGSNNAKWBL-KRWDZBQOSA-N (R)-5F-MDMB-PINACA 
PWEKNGSNNAKWBL-QGZVFWFLSA-N (S)-5F-MDMB-PINACA
The REACH registered substances database hosted by the 
European Chemicals Agency (ECHA) was searched using the 
CAS registry numbers listed above. The searches returned no 
hits.
(12) The Chemical Abstract Service Registry Number (CAS RN) is a unique 
numeric identifier assigned by the Chemical Abstract Service Division of the 
American Chemical Society to a specific, single chemical substance.
(13) InChI Key is a unique, non-proprietary stuctural identifier of chemical 
substances useful in electronic sources.
FIGURE 1 
Molecular structure, molecular formula and molecular mass of 5F-MDMB-PINACA. Information on MDMB-CHMICA is provided 
for comparison.
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Physical description
In its pure form, 5F-MDMB-PINACA is a white solid (Banister 
et al., 2016). It is soluble in dichloromethane (DCM), methanol 
(MeOH) and partially soluble in water (Slovenian National 
Forensic Laboratory, 2016). It is soluble up to approximately 
25 mg/mL in ethanol, dimethyl sulfoxide (DMSO) and dimethyl 
formamide (DMF) and sparingly soluble in aqueous buffers 
(Cayman Chemical Company).
The measured melting point for 5F-MDMB-PINACA is 64-66°C 
(Banister et al., 2016). The boiling point has been estimated to 
be below 350°C according to its retention time in GC-MS 
analysis (Moosmann et al., 2017).
5F-MDMB-PINACA has been typically seized as a herbal 
material and in powder form. It has also been detected in 
liquids and blotters. A more detailed description of seizures 
and collected samples can be found in section 3.2.1 and 
section 3.2.2.
Chemical stability and typical reactions
For long term storage it is recommended that 5F-MDMB-
PINACA, supplied as a solution in acetonitrile, is stored 
at -20°C (Cayman Chemical Company).
Storage under non-ideal conditions (e.g. high humidity or 
elevated temperatures) or in solution can lead to hydrolysis of 
the carboxylic ester function. Ester hydrolysis can also be 
expected to occur during smoking (Moosmann et al., 2017).
Detection and analysis
Reference materials are claimed to be available for (R)-5F-
MDMB-PINACA (14) and for (S)-5F-MDMB-PINACA (15).
Methods documented in the literature for the detection of 
5F-MDMB-PINACA include:
 ¡ gas chromatography–mass spectrometry (GC-MS), high 
performance liquid chromatography time-of-flight (HPLC-
TOF), Fourier transform infrared spectroscopy attenuated 
total reflectance (FTIR-ATR), gas chromatography – mass 
spectrometry– infrared (GC-MS-IR) condensed phase and 
ion chromatography (IC) applied to the analysis of powder 
(Slovenian National Forensic Laboratory 2017)
 ¡ GC-MS, high-resolution mass spectrometry (GC–HRMS), 
ultra-high-performance liquid chromatography–high-
resolution tandem mass spectrometry (UHPLC–HRMS) 
(14) Cayman Chemical Company. ‘5-fluoro ADB’, https://www.caymanchem.com/
product/16603 
(15) Chiron. However, the CAS number (1715016-75-3) listed for the (S) 
enantiomer corresponds to the racemate. http://shop.chiron.no/main.aspx?page
=article&artno=C11345.20-10MG&gid=13277&gidlevel=3&pid=
and 1H and 13C nuclear magnetic resonance spectroscopy 
(NMR) applied to powder and plants (Shevyrin et al., 2015)
 ¡ liquid chromatography–tandem mass spectrometry (LC–
MS–MS) and GC-MS applied to biological samples 
(Hasegawa et al., 2015).
Quantification of 5F-MDMB-PINACA in products can be 
carried out according to the general procedure described by 
the UNODC (UNODC, 2013).
 3.2  Information on the frequency, circumstances 
and/or quantities in which a new psychoactive 
substance is encountered, and information on the 
means and methods of manufacture of the new 
psychoactive substance (Article 5.2(b) of the 
Council Decision)
The data reported to Europol discussed in section 3.2.1 may 
overlap with the data reported to the EMCDDA discussed in 
section 3.2.2.
3.2.1 Information provided to Europol
Europol received replies from 15 Member States (Austria, 
Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Finland, 
Germany, Greece, Latvia, Lithuania, Luxembourg, Romania, 
Slovakia and Slovenia).
Five countries reported that they have no available information 
on 5F-MDMB-PINACA (Croatia, Cyprus, Greece, Latvia and 
Luxembourg).
The remaining 10 countries provided information on 
5F-MDMB-PINACA (Austria, Belgium, Bulgaria, Czech 
Republic, Finland, Germany, Lithuania, Romania, Slovakia and 
Slovenia).
The level of production
No information was received in relation to the production of 
5F-MDMB-PINACA.
The level of distribution
 ¡ At least 240 seizures were reported by nine Member States: 
Austria (3), Belgium (6), Bulgaria (1), Czech Republic (2), 
Finland (exact number unspecified), Germany (220), 
Lithuania (4), Romania (at least 2, exact number 
unspecified) and Slovakia (1). Slovenia reported a collected 
sample (section 3.2.2);
 ¡ Austria: 3 seizures made in 2016, the country of origin was 
China;
 ¡ Belgium: 6 customs seizures made in 2017 at Bierset 
airport, amounting to 2.55 kg;
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 ¡ Bulgaria: 1 seizure of powder amounting to 10 g, which was 
delivered from Spain to Bulgaria in a package labelled ‘5F 
ADB 10g Legal Research Chemical Reagent Use Only’;
 ¡ Czech Republic: 2 seizures made in 2016 and 2017, via 
express courier to Israel, amounting to 498 and 445 g, 
respectively;
 ¡ Finland: unspecified number of seizures made in 2016;
 ¡ Germany: 189 small seizures made in 2016, most of which 
were in the form of herbal material (‘legal high’ products); 
and 31 seizures in 2017, most of which were in the form of 
herbal material. One of the seizures in 2017 was made by 
customs and amounted to over 1 kg of powder;
 ¡ Lithuania: 4 seizures made in 2017, which amounted to 
almost 2 kg;
 ¡ Romania: reported and unspecified number of seizures in 
2015 and 2016, amounting to over 2 and 10 kg, 
respectively;
 ¡ Slovakia: 1 seizure of lump material made in 2017, 
amounting to 500 g.
The level of trafficking
Information related to trafficking routes is limited to the 
seizures reported above.
3.2.2 Information provided to the EMCDDA
The EMCDDA received responses from 27 Member States (5), 
as well as from Turkey and Norway. Of these, 26 Member 
States, Turkey and Norway (16) reported detections of 
5F-MDMB-PINACA (17).
It is important to note that detections of 5F-MDMB-PINACA 
may be under-reported since the substance is not routinely 
screened for. Three Member States (Austria, Slovenia and 
Sweden) and Norway reported that 5F-MDMB-PINACA is part 
of routine screening in some (but not all) of their laboratories.
Seizures
In total, 1 986 seizures of 5F-MDMB-PINACA were reported to 
the EMCDDA by 21 Member States, Norway and Turkey: 
Austria (1 seizure), Belgium (9), Bulgaria (11), Czech Republic 
(1), Denmark (1), Estonia (1), Finland (8), France (16), Germany 
(1), Greece (3), Hungary (252), Ireland (36), Lithuania (27), 
Latvia (1), Malta (3), the Netherlands (1), Poland (58), Romania 
(3), Spain (8), Sweden (71), the United Kingdom (1252), 
(16) Two Member States (Cyprus and Slovakia) reported no detections of 
5F-MDMB-PINACA.
(17) ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples that are analytically confirmed. Seizure 
means a substance available (seized) through law enforcement activities (police, 
customs, border guards, etc.). Collected samples are those that are actively 
collected by drug monitoring systems (such as test purchases) for monitoring 
and research purposes. Biological samples are those from human body fluids 
(urine, blood, etc.) and/or specimens (tissues, hair, etc.). 
Norway (13) and Turkey (209) (18). The majority of the seizures 
comprise police and customs cases, with additional seizures 
taking place in custodial settings.
Seizures included herbal materials, powders, liquids, blotters 
and unspecified physical forms. A summary is provided below.
Herbal material
 ¡ 1 485 seizures of 5F-MDMB-PINACA in herbal material 
were reported by 16 countries: Bulgaria, Germany, Greece, 
Finland, France, Hungary, Ireland, Lithuania, Latvia, Malta, 
Norway, Poland, Romania, Spain, Sweden and the United 
Kingdom, amounting to 26 kg seized (19). In addition, Turkey 
reported 209 seizures of herbal material amounting to 
almost 74 kg (20).
 ¡ The largest single seizures of 5F-MDMB-PINACA in herbal 
material were reported by: Romania (2.9 kg which also 
contained MDMB-CHMICA) and the United Kingdom 
(2.4 kg).
 ¡ In 2 seizures reported by Police Scotland (UK), a total of 
7 669 sealed foil packages (~10 kg), of commercially 
labelled herbal materials were seized. The following 
products were seized: ‘Exodus Damnation 1G’ (5 198 
packages), ‘Exodus Damnation 3G’ (1 106 packages), 
‘Exodus Nightshade 1G’ (1 197 packages), ‘Exodus 
Nightshade 3G’ (168 packages), ‘Vertex Space Cadet 
Edition 1G’ (20 packages). A small number of samples of 
each product were analysed and were found to contain 
5F-MDMB-PINACA, mixed with 5F-AMB-PICA (not 
confirmed analytically).
 ¡ In the herbal materials seized, 5F-MDMB-PINACA was 
commonly found mixed with other synthetic cannabinoids. 
In two cases reported by the United Kingdom, the synthetic 
opioid U-47,700 was also detected in herbal materials 
mixed with 5F-MDMB-PINACA.
 ¡ The United Kingdom reported 129 seizures of 5F-MDMB-
PINACA that took place in a prison or other custodial 
setting, amounting to a total of 3 kg of mostly herbal 
material and often in combination with other synthetic 
cannabinoids.
Powder
 ¡ 77 seizures of powder were reported by 12 countries 
(Belgium, Bulgaria, Czech Republic, Finland, France, 
Hungary, Ireland, Lithuania, the Netherlands, Poland, 
Sweden and the United Kingdom) amounting to a total of 
more than 13.4 kg.
 ¡ The largest single seizures of 5F-MDMB-PINACA in powder 
form were reported by: Bulgaria (2 kg of white powder, 
seized in April 2016 by customs at Sofia Airport), France 
(18) Minimum estimate provided by the Turkish national focal point.
(19) No amounts were reported for 686 detections reported by LGC in the UK for 
the year 2016, so the total amount is likely to be considerably higher.
(20) This is a minimum estimate provided by the Turkish National Focal Point.
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(2 seizures over 2 kg, one of which was 2.3 kg of brown 
powder seized by customs in March 2017 at Roissy airport) 
and the Netherlands (2 kg seized by customs). Additionally, 
8 customs seizures of powders weighing more than 1 kg 
each were reported by Belgium (2 seizures) and France (2). 
The seizures were all carried out at international airports.
Liquid
 ¡ Nine seizures of 5F-MDMB-PINACA in liquid form were 
reported by six countries: Denmark, Estonia, Finland, 
Norway, Sweden and the United Kingdom, amounting to 
a total 309.2 g and 94 ml seized.
 ¡ In a 274 g seizure reported by the UK, the liquid (clear and 
yellow) also contained U-47,700.
 ¡ Two bottles (of 5 ml each) of C-liquid for vaping were seized 
by customs in Denmark. The bottles originated in Spain, 
with Denmark as the final destination.
 ¡ Two bottles (7 ml each) of a pink liquid named “SKITTLES” 
were seized by Norwegian customs.
Other physical forms
 ¡ Small amounts of 5F-MDMB-PINACA in blotter form were 
reported by Poland (2 seizures) and Lithuania (1).
 ¡ Additionally, in 287 cases, amounting to more than 3.5 kg, 
the physical form was unspecified.
Quantitative information on purity of 5F-MDMB-PINACA in 
seized samples was reported by Lithuania for two samples of 
powder: 96 % purity (for a sample of 141.01 g) and 91 % 
(sample of 0.9835 g).
Collected samples
Nine collected samples were reported by five Member States: 
Germany (4 cases), Italy (1), Luxembourg (1), Slovenia (1) and 
the United Kingdom (2). The detections included small 
amounts of herbal material, powder and one joint. Where 
reported, the samples were either collected in relation to cases 
of acute intoxications or as test purchases from online vendors.
The sample reported by Slovenia consisted of 5 g of white 
powder purchased as ‘5F-NPB-22’ and shipped from 
Germany.
The United Kingdom reported a test purchase of a product 
named ‘K2 Black edition’, purchased from a domestic website.
Biological samples
Serious adverse events with confirmed exposure to 
5F-MDMB-PINACA from biological samples are discussed in 
section 3.4.2.
In addition to these, 84 detections where 5F-MDMB-PINACA 
was analytically confirmed in biological samples were 
reported by two Member States: Hungary (83) and 
Sweden (1) (21). Detections include:
 ¡ 15 cases of persons suspected of driving under the influence of 
drugs (including three traffic accidents), all reported by Hungary;
 ¡ 69 cases reported as aggregated data associated with 
forensic case work (details not specified).
 3.3  Information on the involvement of organised 
crime in the manufacture or trafficking of the new 
psychoactive substance (Article 5.2(c) of the 
Council Decision)
No information concerning the involvement of organised crime 
in the manufacture and/or trafficking of the 5F-MDMB-
PINACA was provided.
Money laundering aspects
No information was received on money laundering in connection 
with the production and/or trafficking of 5F-MDMB-PINACA.
Violence in connection with production, wholesale and 
distribution
No information was received on incidents of violence in 
connection with the production, wholesale and/or trafficking 
of 5F-MDMB-PINACA.
 3.4  A first indication of the risks associated with the 
new psychoactive substance, including the health 
and social risks, and of the characteristics of 
users — Article 5.2(d) of the Council Decision
3.4.1 Health risks
Pharmacology and toxicology
Limited data suggests that 5F-MDMB-PINACA is a CB
1
 
receptor agonist (Banister et al., 2016; Moosmann et al., 2017; 
US DEA, 2016 (22)) that shares some similarities with the 
major psychoactive constituent of cannabis (–)-trans-Δ9-
tetrahydrocannabinol (THC) and synthetic cannabinoids such 
as JWH-018 and MDMB-CHMICA (EMCDDA, 2017; Järbe and 
Raghav, 2017; Pertwee, 2014; Reggio, 2009).
(21) In addition, Turkey reported 113 samples (blood, hair and urine) which may 
contain duplicates and therefore have not been included in the total count. 
(22) Where reported the (S) enantiomer was studied.
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The acute effects of THC (and consequently cannabis) include: 
relaxation, euphoria, lethargy, depersonalisation, distorted 
perception of time, impaired motor performance, 
hallucinations, paranoia, confusion, fear, anxiety, dry mouth, 
reddening of the conjunctivae of the eyes, tachycardia, nausea 
and vomiting. THC also has an abuse liability and dependence 
potential (Pertwee, 2014; Wiley et al., 2016). Similar effects to 
cannabis have been reported for synthetic cannabinoids such 
as 5F-MDMB-PINACA. In some cases, the effects are reported 
to be more pronounced/severe (EMCDDA, 2017b).
Compared to cannabis, severe and fatal poisoning appears to 
be more common with synthetic cannabinoids (EMCDDA, 
2017b; Tait et al., 2016). Poisoning may include rapid loss of 
consciousness/coma, cardiovascular effects (such as 
hypertension, tachycardia, bradycardia, chest pain, myocardial 
infarction and stroke), seizures and convulsions, vomiting/
hyperemesis, delirium, agitation, psychosis and aggressive and 
violent behaviour. Sudden death has also been reported. The 
mechanisms of this toxicity are poorly understood (Tai and 
Fantegrossi, 2016), but factors that are likely to play an 
important role are the potency of the substances and the 
doses that users are exposed to. In addition, some of the 
effects of poisoning — such as loss of consciousness or 
behavioural effects — may place users at additional risks such 
as choking on vomitus, drowning or self-harm.
There is no antidote to poisoning caused by synthetic 
cannabinoids.
In general, the use of herbal smoking mixtures containing 
synthetic cannabinoids appears to pose a high risk of 
poisoning. This is because manufacturers guess the amount of 
cannabinoid(s) to add to the herbal material and the 
manufacturing process makes it difficult to dilute them 
sufficiently and distribute them consistently throughout the 
material. This can result in mixtures that contain a large 
amount of highly potent cannabinoid, as well as ‘hot pockets’ 
where the cannabinoid is highly concentrated within parts of 
the herbal material (e.g. Schäper et al., 2016). Together, this 
makes it difficult for users to control the dose that they are 
exposed to. As these mixtures are typically smoked as 
cigarettes (‘joints’), users can inadvertently administer a toxic 
dose; in some cases, a small number of puffs from a cigarette 
have been sufficient to cause severe poisoning. Reflecting 
these risks, smoking mixtures have caused a large number of 
outbreaks of mass poisonings in recent years (Adams et al., 
2017; Kasper et al., 2015; Schwartz et al., 2015; Shevyrin et al., 
2015; Trecki et al., 2015; Tyndall et al., 2015).
While there is limited data for 5F-MDMB-PINACA, the chronic 
health risks might share similarities to cannabis and other 
synthetic cannabinoids. This may include dependence.
3.4.2 Serious adverse events
Acute intoxications
A total of 35 acute intoxication with confirmed exposure to 
5F-MDMB-PINACA were reported by Hungary (1 case) and the 
United Kingdom (34 cases) (23). The cases occurred during 
2016. No further details are available on the case from 
Hungary.
In six of the cases from the United Kingdom, no other 
substances were detected. In the remaining cases, other 
synthetic cannabinoids (detected in 20 cases) and opioids 
(with methadone detected in 19 cases) were typically 
detected. Overall, many of the cases included clinical features 
of poisoning similar to those reported for synthetic 
cannabinoids.
Deaths
A total of 24 deaths with confirmed exposure to 5F-MDMB-
PINACA were reported by Germany (16 cases) and United 
Kingdom (8). The cases occurred between 2015 and 2017.
Of the deaths, 22 were male (92 %), one was female (4 %); the 
data was missing for one case (4 %). The males were aged 
between 22 and 49 years (mean 33.1, median 31.5); the 
female was aged 48.
In five cases, no other substances were detected. In the 
remaining cases, other substances were detected; for many 
this included central nervous system depressants (such as 
alcohol, synthetic cannabinoids and opioids). Where known, 
many of the cases were found dead; in at least some cases 
the individuals were in a home environment or prison. In at 
least 14 cases, 5F-MDMB-PINACA was the cause of death or 
contributed to the death.
3.4.3 Characteristics of users
Similar to other synthetic cannabinoids, 5F-MDMB-PINACA is 
sold and used as a ‘legal’ substitute for cannabis (EMCDDA, 
2009; EMCDDA, 2017). The most common way of using it is by 
smoking a cigarette of herbal mixture that has been laced with 
the substance. Because these products rarely state the 
ingredients, most users will be unaware that they are using 
5F-MDMB-PINACA.
People who use 5F-MDMB-PINACA may include recreational 
users, high-risk drug users and groups who experiment with 
the substance (such as psychonauts). This may also include 
(23) In addition, Germany reported 5 acute intoxications with possible exposure to 
ADB-CHMINACA and Italy reported 1 acute intoxication with possible exposure 
to ADB-CHMINACA. These cases are not discussed further in this report.
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individuals who are subject to drug testing (such as people in 
drug treatment, prisoners and drivers) because some drug 
tests/screens will be unable to detect 5F-MDMB-PINACA. In 
the past few years, synthetic cannabinoids have become 
increasingly used by vulnerable groups (such as the homeless 
and prisoners).
3.4.4 Social risks
While there is limited data for 5F-MDMB-PINACA, the social 
risks might share some similarities with cannabis and other 
synthetic cannabinoids.
Of particular note is that synthetic cannabinoids are 
increasingly used by vulnerable groups, such as the homeless 
and prisoners. Reports suggest that this has caused new 
health and social problems as well as exacerbated existing 
ones for these groups. For example, in prisons, alongside the 
adverse health effects, the market in synthetic cannabinoids 
has been linked to an increase in aggression, violence, bullying 
and debt. In some cases this has caused a serious threat to 
the overall safety and security of the prison environment 
(Blackman et al., 2017; HMIP, 2015; Ralphs et al., 2017; User 
Voice, 2016).
 3.5  Information on whether or not the new substance 
is currently under assessment, or has been under 
assessment, by the UN system (Article 5.2(e) of 
the Council Decision)
The World Health Organization is the specialised United 
Nations agency designated for the evaluation of the medical, 
scientific and public health aspects of psychoactive 
substances under the Single Convention on Narcotic Drugs, 
1961 and the Convention on Psychotropic Substances, 1971.
On 1 May 2017, the World Health Organization (WHO) 
informed the EMCDDA that 5F-MDMB-PINACA is currently not 
under assessment and has not been under assessment by the 
UN system.
On 12 May 2017, the WHO informed the EMCDDA that 
‘5F-ADB’ will be assessed at the 39th meeting of the WHO 
Expert Committee on Drug Dependence (ECDD) that will be 
held on 16–20 November 2017. At the time of writing this 
report neither a critical review nor a written recommendation 
had been published.
 3.6  The date of notification on the Reporting Form of 
the new psychoactive substance to the EMCDDA 
or to Europol (Article 5.2(f) of the Council 
Decision)
The first official EMCDDA–Europol notification of 5F-MDMB-
PINACA dates from 8 January 2015 from the Hungarian 
national focal point. The Reporting Form details a seizure of 
0.79 g of white powder that was seized in September 2014 by 
the National Tax and Customs Administration Airport 
Directorate Nr.1, in Budapest. The substance was analytically 
confirmed by GC-MS and Fourier transform infrared 
spectroscopy (FT-IR).
5F-MDMB-PINACA was added to the list of new psychoactive 
substances monitored by the EMCDDA and Europol through 
the European Union Early Warning System. A profile of the 
substance was created on the European Database on New 
Drugs (EDND). Since then, analytical details and other 
information, including a public health alert, have been 
exchanged between the EMCDDA, Europol, and the Member 
States, Turkey and Norway, on an ad hoc basis; the European 
Commission and the EMA have been kept duly informed.
 3.7  Information on whether or not the new 
psychoactive substance is already subject to 
control measures at national level in a Member 
State (Article 5.2(g) of the Council Decision)
Twelve Member States (Bulgaria, Croatia, Cyprus, Czech 
Republic, Estonia, Finland, France, Germany, Latvia, Lithuania, 
Luxembourg and Sweden) reported that 5F-MDMB-PINACA is 
controlled under drug control legislation.
Three Member States (Austria, Hungary and Poland) and 
Turkey reported that 5F-MDMB-PINACA is controlled under 
specific new psychoactive substances control legislation.
Twelve Member States (Belgium, Denmark, Greece, Ireland, 
Italy, Malta, the Netherlands, Portugal, Romania, Slovenia, 
Spain and the United Kingdom) reported that 5F-MDMB-
PINACA is not subject to control measures at the national 
level.
Norway reported that 5F-MDMB-PINACA is controlled under 
medicinal products legislation.
Slovakia did not provide information on the control status of 
5F-MDMB-PINACA.
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 3.8  Further information (Article 5.2(h) of the 
Council Decision)
3.8.1  The chemical precursors that are known to have 
been used for the manufacture of the substance
No information was reported by the Member States, Turkey or 
Norway, about the chemical precursors or manufacturing 
methods used to make the 5F-MDMB-PINACA which has 
been detected within Europe.
The synthesis of (S)-5F-MDMB-PINACA enantiomer was 
described by Banister et al. starting from the commercially 
available methyl 1H-indazole-3-carboxylate which was 
reacted with methyl L-tert-leucinate (Banister et al., 2016). 
Other 1H-indazole-3-carboxylic acid esters might be suitable 
as alternative starting materials. The (R) enantiomer might be 
synthesised under identical conditions using methyl D-tert-
leucinate instead of methyl L-tert-leucinate. Using methyl 
tert-leucinate as a racemate would lead to racemic 5F-MDMB-
PINACA. The reported synthesis route is comparable to the 
way Buchler et al. described the synthesis of other structurally 
related indazole derivatives in a patent application (Buchler et 
al., 2009).
According to Buchler et al. (Buchler at al., 2009) the starting 
compound methyl 1H-indazole-3-carboxylate, which is 
commercially available, can be prepared from 1H-indole-2,3-
dione using the procedure of Johnson et al. (Johnson et al., 
2005).
In summary, potential precursors of 5F-MDMB-PINACA are 
1H-indole-2,3-dione (24), 1H-indazole-3-carboxylic acid, 
methyl 1H-indazole-3-carboxylate, methyl l-tert-leucinate 
(for synthesis of the (S)-enantiomer) and 1-bromo-5-
fluoropentane (Moosmann et al., 2017).
3.8.2  The mode and scope of the established or 
expected use of the new substance
No studies were identified that have examined the mode and 
scope of established or expected use of 5F-MDMB-PINACA. 
Given the limited information currently available, the relevant 
information has been included in the previous sections.
(24) A pre-precursor.
3.8.3  Other use of the new psychoactive substance 
and the extent of such use, the risks associated 
with this use of the new psychoactive 
substance, including the health and social risks
No information was provided by the Member States, Turkey or 
Norway that indicated that 5F-MDMB-PINACA had any other 
use apart from in analytical reference materials and scientific 
research.
From the available information, it does not appear that 
5F-MDMB-PINACA is used in the manufacture of a medicinal 
product in the European Union. However, the data collection is 
incomplete and some countries indicated that this information 
is not known. It is understood that the collection of such 
information is a challenge in the absence of a database on the 
synthetic route of all medicinal products.
Eleven countries (Austria, Belgium, Croatia, Denmark, Finland, 
Greece, Italy, the Netherlands, Poland, Spain and the United 
Kingdom) reported that 5F-MDMB-PINACA is not used to 
manufacture a medicinal product for human use. Eight 
countries (Czech Republic, Estonia, Germany, Hungary, 
Ireland, Latvia, Norway and Sweden) reported that it was 
unknown if 5F-MDMB-PINACA is used to manufacture 
a medicinal product for human use.
In addition, the EMA reported that it is not known if 5F-MDMB-
PINACA is used in the manufacture of medicinal products for 
human use and which are centrally authorised within the 
European Union.
Eleven countries (Austria, Belgium, Denmark, Finland, France, 
Greece, Latvia, Poland, Slovakia, Spain and the United 
Kingdom) provided information that 5F-MDMB-PINACA is not 
used to manufacture a medicinal product for veterinary use. 
Seven countries (Estonia, Germany, Ireland, Norway, Portugal, 
Slovenia and Sweden) reported that it was unknown if 
5F-MDMB-PINACA is used to manufacture a medicinal 
product for veterinary use.
In addition, the EMA reported that it is not known if 5F-MDMB-
PINACA is used in the manufacture of medicinal products for 
veterinary use and which are centrally authorised within the 
European Union.
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 4.  Information from the EMA (Article 5.3 
of the Council Decision)
Nineteen countries (Austria, Belgium, Croatia, Czech Republic, 
Denmark, Estonia, Finland, Germany, Greece, Hungary, 
Ireland, Italy, Latvia, the Netherlands, Norway, Poland, Spain, 
Sweden and the United Kingdom) reported that:
 ¡ 5F-MDMB-PINACA has not been granted a marketing 
authorisation as a medicinal product for human use;
 ¡ 5F-MDMB-PINACA is not the subject of an application for 
a marketing authorisation as a medicinal product for human 
use;
 ¡ there had been no cases of suspended marketing 
authorisation in respect to 5F-MDMB-PINACA as a human 
medicine.
Eighteen countries (Austria, Belgium, Denmark, Estonia, 
Finland, France, Germany, Greece, Ireland, Latvia, Norway, 
Poland, Portugal, Slovakia, Slovenia, Spain, Sweden and the 
United Kingdom) reported that:
 ¡ 5F-MDMB-PINACA has not been granted a marketing 
authorisation as a medicinal product for veterinary use;
 ¡ 5F-MDMB-PINACA is not the subject of an application for 
a marketing authorisation as a medicinal product for 
veterinary use;
 ¡ there had been no cases of suspended marketing 
authorisation in respect to 5F-MDMB-PINACA as 
a veterinary medicine.
The EMA also reported that 5F-MDMB-PINACA:
 ¡ has not been granted a marketing authorisation as 
a medicinal product for neither human nor veterinary use 
through the centralised procedure;
 ¡ is not the subject of an application for a marketing 
authorisation for neither human nor veterinary use through 
the centralised procedure;
 ¡ is not the subject of a suspended marketing authorisation 
for neither human nor veterinary use through the 
centralised procedure.
I 5. Conclusion
5F-MDMB-PINACA is a synthetic cannabinoid and a CB
1
 
receptor agonist. It shares some pharmacological similarities 
with Δ9-tetrahydrocannabinol (THC), which is responsible for 
the major psychoactive effects of cannabis. In humans, 
5F-MDMB-PINACA appears to cause effects that resemble 
those of cannabis and other synthetic cannabinoids.
5F-MDMB-PINACA has been available in the European Union 
since at least September 2014 and has been detected in 26 
Member States, Turkey and Norway. More than 1 700 seizures 
have been made within the European Union, which include 
over 13 kg of powder and 26 kg of herbal material which has 
been laced with 5F-MDMB-PINACA. This herbal material is 
typically sold as smoking mixtures; the products are marketed 
as ‘legal’ replacements to cannabis. Due to the way that these 
products are produced, it appears that users are at risk of 
serious poisoning. There are indications that the 5F-MDMB-
PINACA available on the market was synthesised by chemical 
companies based in China.
Twenty-four deaths with confirmed exposure to 5F-MDMB-
PINACA have been reported by two Member States. In at least 
14 of the deaths, 5F-MDMB-PINACA was the cause of death 
or contributed to the death.
5F-MDMB-PINACA is under assessment within the United 
Nations system. It will be assessed at the 39th meeting of the 
WHO Expert Committee on Drug Dependence (ECDD) that 
will be held in November 2017. Currently, neither a critical 
review nor a written recommendation had been published. 
5F-MDMB-PINACA is not subject to control measures in nine 
Member States.
We conclude that the health and social risks caused by the 
manufacture, trafficking and use of 5F-MDMB-PINACA and 
the involvement of organised crime and possible 
consequences of control measures, could be thoroughly 
assessed through a risk assessment procedure in accordance 
with Article 6 of Council Decision 2005/387/JHA.
The EMCDDA and Europol will continue to intensively monitor 
5F-MDMB-PINACA in order to ensure that new information is 
provided to the Member States, the EMA and the Commission 
via the information exchange of the European Union Early 
Warning System.
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I  Annex 1 Images from seizures and collected samples provided to the EMCDDA
Country Image Description
France Seizure, 04 February 2016
Green herbal mixture, seized at Saint 
Denis airport (La Réunion)
Seizing authority: Customs
Norway
  
Seizure, 29 February 2016
Herbal mixture in package labelled 
“Dutchy”, seized in Lørenskog
Seizing authority: Customs
United Kingdom Collected sample, 10 March 2016
Green herbal mixture
Collecting authority: TICTAC 
Communications
Slovenia Collected sample, 20 December 2016
White powder
Collecting authority: project RESPONSE
(note: sample was purchased as 
5F-NPB-22)
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